KRAS and familial adenomatous polyposis 2: Notably, most MAP cases (11/15) were not previously diagnosed, demonstrating that the strong association between KRAS‐G12C mutations and the presence of MUTYH GPVs supports its use as a biomarker for referring patients to germline MUTYH testing, enabling appropriate follow‐up, surveillance and preventive strategies for individuals at risk.